Resources Available for Patients with HIV Drug Resistance

Opinion
Video

The panel concludes its discussion by talking about resources available for providers in managing their patients with HIV who experience drug resistance.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      BIC = bictegravir

      DRV = darunavir

      DTG = dolutegravir

      F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

      F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

      B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

      DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

      DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

      D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

      DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

      CAB = Cabotegravir

      CAB + RPV = Cabotegravir + Rilpivirine

      Video content above is prompted by the following question:

      • When resistance occurs, what resources can health care providers use to help patients in their treatment journey?

      Newsletter

      Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

      © 2025 MJH Life Sciences

      All rights reserved.